Bluejay Diagnostics (BJDX) Notes Payables (2020 - 2024)
Bluejay Diagnostics (BJDX) reported Notes Payables of $147440.0 for Q2 2024, down 5.26% sequentially from $155629.0 in Q4 2020.
Bluejay Diagnostics (BJDX) Notes Payables (2020 - 2024) Analysis & Trends
Bluejay Diagnostics (BJDX) has 2 years of Notes Payables data on file, last reported at $147440.0 in Q2 2024.
- For the quarter ending Q2 2024, Notes Payables changed N/A year-over-year to $147440.0; the trailing twelve-month figure through Jun 2024 stood at $147440.0 (changed N/A YoY), and the FY2020 full-year result was $155629.0, changed N/A from the prior year.
- Notes Payables fell to $147440.0 in Q2 2024, from $155629.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $155629.0 in Q4 2020 to a low of $147440.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Bluejay Diagnostics | 2,754.24 | 2,754.24 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 147,440.00 |
| Dec 31, 2020 | 155,629.00 |